Damora Therapeutics (DMRA) Stock Overview
A biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
DMRA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Damora Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.09 |
| 52 Week High | US$38.33 |
| 52 Week Low | US$2.01 |
| Beta | 1.57 |
| 1 Month Change | -10.65% |
| 3 Month Change | 14.99% |
| 1 Year Change | 777.27% |
| 3 Year Change | -47.18% |
| 5 Year Change | -82.84% |
| Change since IPO | -93.31% |
Recent News & Updates
Recent updates
Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?
Jan 10
Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely
May 17Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?
Feb 01Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer
Oct 19Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation
Oct 19Galecto GAAP EPS of -$0.67 beats by $0.02
Jul 29We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate
Jun 30Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?
Mar 10Galecto: Selling At Cash Value
Dec 19We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate
Nov 18Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation
Jul 07We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth
Mar 23Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?
Jan 29
Shareholder Returns
| DMRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.1% | 2.4% | 1.9% |
| 1Y | 777.3% | 33.3% | 23.7% |
Return vs Industry: DMRA exceeded the US Biotechs industry which returned 31.7% over the past year.
Return vs Market: DMRA exceeded the US Market which returned 16.1% over the past year.
Price Volatility
| DMRA volatility | |
|---|---|
| DMRA Average Weekly Movement | 18.0% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: DMRA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DMRA's weekly volatility has decreased from 67% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 7 | Jen Jarrett | www.damoratx.com |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.
Damora Therapeutics, Inc. Fundamentals Summary
| DMRA fundamental statistics | |
|---|---|
| Market cap | US$1.51b |
| Earnings (TTM) | -US$209.84m |
| Revenue (TTM) | n/a |
Is DMRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$209.84m |
| Earnings | -US$209.84m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.48 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DMRA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/02 05:40 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Damora Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Gavin Clark-Gartner | Evercore ISI |
| Bradley Canino | Guggenheim Securities, LLC |